Diabetes drug pioglitazone may prevent recurring strokes
18 February 2016 | By Victoria White
A new study has found that pioglitazone may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes...
List view / Grid view
News
PerkinElmer Signals™ Perspectives launches in collaboration with Attivio
18 February 2016 | By PerkinElmer Inc
New data discovery solution leverages Attivio’s platform to provide insight into complex scientific challenges...
NICE calls for more research into Alexion’s sebelipase alfa
18 February 2016 | By Victoria White
NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency...
inABLE® technology helps unlock the secrets of cyclic peptides
17 February 2016 | By Ingenza Laboratory
Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use...
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 | By Victoria White
Praxbind (idarucizumab) is now available to be used commercially after the Health Technology Appraisal bodies agreed that it is eligible for full reimbursment without the need for a full appraisal.
New study to investigate PQR309 and eribulin in triple-negative breast cancer
17 February 2016 | By Victoria White
Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin...
Breakthrough Therapy Designation for ocrelizumab in PPMS
17 February 2016 | By Victoria White
Roche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
ICR scientists develop Ecosystem Diversity Index for breast cancers
16 February 2016 | By Victoria White
Scientists have developed a test called the Ecosystem Diversity Index which combines methods used by ecologists with a powerful cancer imaging technique...
FDA accepts Teflaro sNDA for filing
16 February 2016 | By Victoria White
If approved, this filing will expand the label of Teflaro beyond adults to include the treatment of children two months of age and older...
‘Extraordinary’ t-cell therapy results could change the face of cancer treatment
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
Growth in Finished Dosage Formulations sees CPhI Worldwide introduce new event
16 February 2016 | By CPhI Worldwide
CPhI Worldwide formally introduces a new co-located event entirely dedicated to Finished Dosage Formulation (FDF) following a soft launch amongst exhibitors in 2015...
Golimumab shows higher treatment persistence rates in patients with IMRD
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
Amgen’s Phase 3 Aranesp trial in MDS meets primary endpoint
16 February 2016 | By Victoria White
Aranesp reduced the incidence of red blood cell transfusions in anaemic patients with low and intermediate-1 risk myelodysplastic syndrome...
Zepatier to threaten the dominance of Harvoni in the HCV market
15 February 2016 | By Victoria White
A GlobalData analyst says that the combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake...
Easy and quick HPLC analysis of Aflatoxin in milk
Aflatoxins are naturally occurring mycotoxins that are produced by different species of fungi. In addition to the most toxic aflatoxin B1, a number of other related compounds are occurring in nature. High level exposure to aflatoxins can, for example, produce acute hepatic necrosis especially children, whilst adults have higher tolerances.
